Mini-tablets as technological strategy for modified release of morphine sulfate
This study aimed to use an intelligent formulation design for the development of mini-tablets for the modified release of morphine sulfate. A formulation (F1) was proposed using the Hiperstart® software. Based on the suggested formulation, two other formulations (F2 and F3) were prepared: one for modified and another for immediate drug release. The powders were characterized as bulk and tapped density, Hausner's factor, and compressibility index analyses. Mini-tablets were directly compressed and characterized by hardness, friability, size, and weight variation. The in vitro drug release profile was carried out according to apparatus 1 of USP. Formulations showed good flow properties, and the mini-tablets displayed characteristics according to the specified. In comparison to F3 (immediate release), F1 and F2 displayed slower drug release time, showing the efficiency of the matrix formed. F3 displayed 90% of drug released up to 10 min, while F1 and F2 required 240 min. The results highlight the importance to use intelligent formulation design for the development of improved mini-tablet matrices. Formulation F1 was found to be suitable for modified morphine sulfate release. Further studies with more formulations are necessary for the production of optimized mini-tablets with suitable prolonged morphine sulfate release.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Pharmaceutical development and technology - 27(2022), 7 vom: 09. Sept., Seite 766-772 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Silva, Raizza Tafet Carminato E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
76I7G6D29C |
|---|
| Anmerkungen: |
Date Completed 19.10.2022 Date Revised 19.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/10837450.2022.2118769 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345363620 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345363620 | ||
| 003 | DE-627 | ||
| 005 | 20231226024909.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10837450.2022.2118769 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1151.xml |
| 035 | |a (DE-627)NLM345363620 | ||
| 035 | |a (NLM)36017971 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Silva, Raizza Tafet Carminato E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mini-tablets as technological strategy for modified release of morphine sulfate |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.10.2022 | ||
| 500 | |a Date Revised 19.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a This study aimed to use an intelligent formulation design for the development of mini-tablets for the modified release of morphine sulfate. A formulation (F1) was proposed using the Hiperstart® software. Based on the suggested formulation, two other formulations (F2 and F3) were prepared: one for modified and another for immediate drug release. The powders were characterized as bulk and tapped density, Hausner's factor, and compressibility index analyses. Mini-tablets were directly compressed and characterized by hardness, friability, size, and weight variation. The in vitro drug release profile was carried out according to apparatus 1 of USP. Formulations showed good flow properties, and the mini-tablets displayed characteristics according to the specified. In comparison to F3 (immediate release), F1 and F2 displayed slower drug release time, showing the efficiency of the matrix formed. F3 displayed 90% of drug released up to 10 min, while F1 and F2 required 240 min. The results highlight the importance to use intelligent formulation design for the development of improved mini-tablet matrices. Formulation F1 was found to be suitable for modified morphine sulfate release. Further studies with more formulations are necessary for the production of optimized mini-tablets with suitable prolonged morphine sulfate release | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Development | |
| 650 | 4 | |a analgesics | |
| 650 | 4 | |a drug delivery | |
| 650 | 4 | |a formulation | |
| 650 | 4 | |a solid dosage form | |
| 650 | 7 | |a Delayed-Action Preparations |2 NLM | |
| 650 | 7 | |a Powders |2 NLM | |
| 650 | 7 | |a Tablets |2 NLM | |
| 650 | 7 | |a Morphine |2 NLM | |
| 650 | 7 | |a 76I7G6D29C |2 NLM | |
| 700 | 1 | |a Bruschi, Marcos Luciano |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmaceutical development and technology |d 1998 |g 27(2022), 7 vom: 09. Sept., Seite 766-772 |w (DE-627)NLM094740194 |x 1097-9867 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2022 |g number:7 |g day:09 |g month:09 |g pages:766-772 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10837450.2022.2118769 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2022 |e 7 |b 09 |c 09 |h 766-772 | ||